Outcomes are reported for 6 adults receiving rezafungin for chronic, hard-to-treat, invasive candidiasis (including Candida parapsilosis) during an early access program. Rezafungin was well tolerated and administered via once-weekly outpatient intravenous infusion for up to 39 weeks during the program, enabling hospital discharge and replacing daily antifungal infusions.
Long-term Safety and Effectiveness of Rezafungin Treatment in Candidemia and Invasive Candidiasis: Results From an Early Access Program in Italy and Germany / Trapani, F.; Viceconte, G.; Morena, V.; Tiseo, G.; Mori, G.; Kolking, B.; Khatamzas, E.. - In: OPEN FORUM INFECTIOUS DISEASES. - ISSN 2328-8957. - 12:3(2025). [10.1093/ofid/ofaf034]
Long-term Safety and Effectiveness of Rezafungin Treatment in Candidemia and Invasive Candidiasis: Results From an Early Access Program in Italy and Germany
Viceconte G.;
2025
Abstract
Outcomes are reported for 6 adults receiving rezafungin for chronic, hard-to-treat, invasive candidiasis (including Candida parapsilosis) during an early access program. Rezafungin was well tolerated and administered via once-weekly outpatient intravenous infusion for up to 39 weeks during the program, enabling hospital discharge and replacing daily antifungal infusions.| File | Dimensione | Formato | |
|---|---|---|---|
|
Trapani et al_2025_OFID.pdf
solo utenti autorizzati
Licenza:
Copyright dell'editore
Dimensione
597.16 kB
Formato
Adobe PDF
|
597.16 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
